Baseline characteristics of trial individuals (n=291)
| Variables | Trial arms | Total | |
| Intervention | Control | ||
| (n=159) | (n=132) | (n=291) | |
| n (%) | n (%) | n (%) | |
| Sociodemographic characteristics | |||
| Age (years)* | 50.7 (7.6) | 50 (7.6) | 50.3 (7.6) |
| Age (categorical) years | |||
| 18–44 years | 32 (20.1) | 32 (24.2) | 64 (22.0) |
| 45–64 years | 127 (79.9) | 100 (75.8) | 227 (78.0) |
| Gender | |||
| Male | 51 (32.1) | 51 (38.6) | 102 (35.1) |
| Female | 108 (67.9) | 81 (61.4) | 189 (64.9) |
| Anthropometric measurement | |||
| Central obesity† | (n=159) | (n=132) | (n=291) |
| Yes (F>80 cm, M>90 cm) | 156 (98.1) | 127 (96.2) | 283 (97.2) |
| No (F≤80 cm, M≤90 cm) | 3 (1.9) | 5 (3.8) | 8 (2.8) |
| Clinical characteristics | |||
| RBS | 164.0 (22.6) | 164.9 (22.6) | 164.4 (22.6) |
| HbA1c* | 5.97 (0.21) | 5.96 (0.21) | 5.97 (0.21) |
| Prediabetic stages | |||
| HbA1c 5.7%–5.9% | 83 (52.2) | 73 (55.3) | 156 (53.6) |
| HbA1c 6.0%–6.4% | 76 (47.8) | 59 (44.7) | 135 (46.4) |
*Mean (SD).
†As per WHO guideline for Central Obesity for Asian population based on waist circumference.
F, female; HbA1c, glycated haemoglobin; M, male; RBS, random blood sugar.